iBio, Inc., a biopharmaceutical company headquartered in Newark, United States, operates within the Health Care sector, specifically focusing on the Biotechnology industry. The company is publicly traded on the Nasdaq exchange, with its financial activities denominated in USD. As of December 25, 2025, iBio’s closing stock price was recorded at USD 1.89. Over the past year, the company’s stock has fluctuated significantly, reaching a 52-week high of USD 6.89 on March 4, 2025, and a 52-week low of USD 0.56 on August 7, 2025.
The market capitalization of iBio stands at USD 42,500,000, reflecting its current valuation in the market. Despite its innovative focus on developing and commercializing plant-made products aimed at preventing and treating serious infectious diseases, the company’s financial metrics indicate challenges. Specifically, iBio’s price-to-earnings (P/E) ratio is negative at -1.26, suggesting that the company is currently not generating profits. Additionally, the price-to-book (P/B) ratio is 0.7945, indicating that the market values the company below its book value.
A recent sector analysis, dated December 29, 2025, highlighted the growing interest in plant-based vaccines, identifying iBio Inc. alongside Medicago, Inc. as significant contributors to this field. This analysis underscores iBio’s strategic positioning within the biotechnology sector, focusing on innovative solutions to address infectious diseases. However, no further corporate events or earnings releases have been reported since this announcement, leaving investors and stakeholders with limited updates on the company’s operational progress or financial performance.
In summary, while iBio Inc. is engaged in promising biotechnological advancements, its current financial indicators reflect a challenging market environment. The company’s focus on plant-made products for infectious disease prevention and treatment remains a critical area of interest, particularly in the context of the broader industry trend towards plant-based vaccines.
